Navigation Links
Wonder drug Dasatinib gives hopes to leukemia patients

The company Bristol-Myers Squibb Co at Boston told the press that the drug Dasatinib has led to reduction in the number of patients with Chronic myeloid leukemia (CML).//

This drug is very effective in the decreasing the leukemia cells from the bone marrow than the previously used drug Gleevec.

Chronic myeloid leukemia (CML) is usually presented in three different stages – Chronic stage, accelerated stage and the blast stage. Dasatinib was tried on all these stages of leukemia patients and the results were Out of the186 patients who are in the chronic stage, 45% of the patients attained complete elimination of the leukemia cells from the marrow.

Out of the 107 patients in the accelerated stage 31% who did not react to Gleevec responded positively to Dasatinib.

Out of the 74% in the blast stage (aggressive form) 29% of the patients attained complete elimination of the leukemia cells.

This is a boon to all those patients who do not react to Gleevec which is the treatment for Leukemia.

This drug will soon reach the markets by the end of the current year or the beginning of the next year.

Gleevec was a Swiss product and in 2001after approved by the Food and Drug Administration, made to the markets as the drug which attacks the BCR-ABL protein which results in the abnormal rise of leukocytes.

But with this drug some patients (20% of CML) did not respond to the drug or initially responded but later became resistant to the drug.

The mechanism of the drug action is that it attacks and prevents several proteins (BCR-ABL & SRC) in the same time. SRC is believed to help the leukemia cells to take the alternate pathway and become resistant to Gleevec, but Dasatinib prevents the action of SRC.

The toxicity level of Dasatinib is not more than Gleevec and it has to be brought in to the market for commercial use as the statistics show that in the current year the number of ch ronic CML patients to be 4600.

The company also relies on this drug to become the most famous cancer Drug Company and increase profit. It is estimated that this drug if put in circulation would yield six hundred million dollars to the company within a period of four years.
'"/>




Related medicine news :

1. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
2. Wonder drug - could end in disaster
3. Have You Ever Wondered How We Perceive Different Sounds?
4. Soy Not Such A Wonder For Health?
5. Have You Ever Wondered Why Male And Female Voices Differ?
6. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
7. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
8. Braces Work Wonders In Setting Crooked Teeth Right
9. Daughter Turns Saviour: Ailing Mother Provided Wonder Drug Herceptin, To Fight Cancer
10. Save Budhia - The Indian Wonder Kid
11. Wonder Drug For Weight Loss Launched In UK
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... PARK , Israel , December 7, 2016 ... today the signing of a memorandum of understanding with Korean company ... between the companies will assist in expediting Kadimastem,s entry into international ... innovative treatment for severe diseases in general and ALS and diabetes ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology: